Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.
about
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 yearsReplicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugsClinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipientsChronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging.Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up.Weaning of immunosuppression in liver transplant recipients.The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantationStructural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation.Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) inductionChronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allograftsRenal dysfunction associated with liver transplantation.The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.Perioperative Management of Cardiac Transplant Recipients Undergoing Noncardiac Surgery: Unique Challenges Created by Advancements in Care.Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group.Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation.Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantationTacrolimus (FK506)-Associated Renal Pathology.Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation.Functional and structural characteristics of experimental FK 506 nephrotoxicity.Overview of FK506 in transplantationChanges in biliary (high-molecular-mass) and liver isoforms of alkaline phosphatase after baboon-to-human liver transplantation.Oral health in liver transplant children administered cyclosporin A or tacrolimus.FK506 conversion for intractable rejection of the liver allograft.Indications for tacrolimus anti-rejection therapy in liver allograft recipients.What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.FK 506 rescue therapy for intractable liver allograft rejection.
P2860
Q28344317-78B7D51B-F5EE-4E8B-B550-9A69D2F11DFEQ28362068-A9BE04DE-8F99-4CD0-8242-65A688FE9253Q28378996-61B7247E-EFBB-46E6-92E7-D3425BB8A3F5Q33951385-BE2866B0-A85F-4EC2-86D3-624A5B67379DQ34231590-50ECD0CE-392E-4132-B4F0-3271D046E20AQ34280897-20F48C8C-38EE-4521-8823-1BD8F7806F8EQ34421352-2B94A0F6-2159-4740-9EBE-EBE35AA97001Q34965243-79F3C2E1-512A-4937-8ECC-F1D7C5FA7488Q34985253-A857AAE2-6BC9-4707-91D7-6241C3482B9BQ35253580-3C8A20D4-7270-450F-A8CB-5A9F71EAE51BQ35607413-F409C843-FC63-4B68-9C2F-5628BA7BBE65Q36680260-DB15CFD4-C03F-4B3F-9C2C-78D6178B32C2Q37181790-A530F46A-60B1-4C4E-983F-9F6403202C29Q38807449-888A786D-983A-4CE9-8FEE-3BE88EC8B2F7Q40630682-8481636F-16EA-4435-B344-DFBEFA49C0F3Q41841314-75D5E4BF-C67A-4589-A3A3-BF84234AC508Q41970570-D1F802C4-832C-4724-875B-57DC16ED65C0Q42010174-7D608DFF-5EEE-4C1A-8C74-1E10DEB5E7FFQ42239470-96E65912-4A0F-4C61-BCC9-6974AABF1A0DQ42557751-DB37AF22-E14E-43D7-AA69-12C88A78C581Q42719296-F622D06B-7CC5-46B7-8074-D585B7BD99B5Q42863968-7F8E4C14-0733-4F9A-B9F8-CC8CF5DC2DE5Q43835319-8C0F93E3-CE65-45CF-AC22-58A06041C2CEQ45984261-16E53316-E8D7-4B86-81F0-564448C4BE7BQ53008580-7173BCEC-608B-4F03-8AA1-6B2C3920E78AQ54078474-172FFB4E-F5EE-4E6A-8D69-F08488337B0DQ54217248-504131E4-85F7-4907-93A3-E83267B8E81E
P2860
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.
description
1992 nî lūn-bûn
@nan
1992 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Conversion of liver allograft ...... thologic study of 96 patients.
@ast
Conversion of liver allograft ...... thologic study of 96 patients.
@en
Conversion of liver allograft ...... thologic study of 96 patients.
@nl
type
label
Conversion of liver allograft ...... thologic study of 96 patients.
@ast
Conversion of liver allograft ...... thologic study of 96 patients.
@en
Conversion of liver allograft ...... thologic study of 96 patients.
@nl
prefLabel
Conversion of liver allograft ...... thologic study of 96 patients.
@ast
Conversion of liver allograft ...... thologic study of 96 patients.
@en
Conversion of liver allograft ...... thologic study of 96 patients.
@nl
P2093
P2860
P50
P1433
P1476
Conversion of liver allograft ...... thologic study of 96 patients.
@en
P2093
D H Van Thiel
J McCauley
K Abu-Elmagd
M Alessiani
P2860
P304
P356
10.1097/00007890-199205000-00017
P577
1992-05-01T00:00:00Z